跳至主要内容
临床试验/NCT01507454
NCT01507454已完成不适用

Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 1,613 人开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,613
试验地点
1
主要终点
Percentage of subjects reporting vaginal symptoms occuring 'often' and 'frequently'

研究概览

简要总结

This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Atrophic vaginitis due to estrogen deficiency
  • Post-menopausal

排除标准

  • 未提供

研究组 & 干预措施

Local treatment

干预措施: estradiol, 25 mcg (Drug)

结局指标

主要结局

Percentage of subjects reporting vaginal symptoms occuring 'often' and 'frequently'

Percentage of subjects reporting 'moderate' and 'severe' vaginal symptoms

次要结局

  • Adverse events

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验